Results 221 to 230 of about 617,669 (345)

Nanomedicine‐Driven Modulation of Reductive Stress for Cancer Therapy

open access: yesAdvanced Science, EarlyView.
This article introduces a novel therapeutic paradigm that deliberately induces reductive stress within tumor cells to exploit their unique biochemical vulnerabilities. It systematically reviews the underlying biological mechanisms, current detection and monitoring techniques, and emerging advanced nanotechnology platforms specifically designed to ...
Yumin Mao   +8 more
wiley   +1 more source

Genetic Regulation of Alternative Polyadenylation Provides Novel Insights into Molecular Mechanisms Underlying Non‐small Cell Lung Cancer

open access: yesAdvanced Science, EarlyView.
Compared with the non‐risk G allele of rs9606, the risk T allele of rs9606 decreases the binding affinity of NUDT21 for LYRM4, triggering 3'UTR shortening that stabilizes LYRM4 mRNA and elevates its expression. Increased LYRM4 expression promoted malignant phenotypes of non‐small cell lung cancer (NSCLC) cells through modulating ferroptosis, supporting
Meng Jin   +11 more
wiley   +1 more source

Correction: Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR. [PDF]

open access: yesOncogene
You B   +13 more
europepmc   +1 more source

HindIII polymorphism in the humanc-sisproto-oncogene [PDF]

open access: green, 1988
R.M. Fourney   +3 more
openalex   +1 more source

Mechanistic Foundations of KRAS‐Driven Tumor Ecosystems: Integrating Crosstalk among Immune, Metabolic, Microbial, and Stromal Microenvironment

open access: yesAdvanced Science, EarlyView.
KRAS mutations dynamically remodel the tumor microenvironment (TME), fostering immunosuppression, metabolic symbiosis, and stromal plasticity. This review dissects how oncogenic KRAS variants sculpt TME networks and explores actionable vulnerabilities. Emerging strategies combining KRAS inhibitors and TME‐editing approaches offer potential to dismantle
Jiayao Ma   +9 more
wiley   +1 more source

Correction: CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers. [PDF]

open access: yesOncogene
Raninga PV   +13 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy